BIONTECH SE revenue for the last year amounted to 3.55 B CHF, the most of which — 3.48 B CHF — came from its highest performing source at the moment, Immunotherapy Technologies, the year earlier bringing 16.82 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought BIONTECH SE 2.74 B CHF, and the year before that — 12.35 B CHF.